U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07401394) titled 'BAR-TAX - Tranexamic Acid in Bariatric Surgery.' on Jan. 27.
Brief Summary: Perioperative bleeding is a relevant complication in bariatric surgery and may lead to hemoglobin decrease, blood transfusions, reinterventions, prolonged hospital stay, and increased healthcare costs. Tranexamic acid (TXA), an antifibrinolytic agent, has demonstrated efficacy in reducing surgical bleeding in several surgical specialties, with a favorable safety profile when appropriately used. However, evidence in bariatric surgery remains limited, particularly considering the intrinsically increased thromboembolic risk of obese patients.
The BAR-TAX study...